{{Rsnum
|rsid=4954956
|Gene=NXPH2
|Chromosome=2
|position=138787007
|Orientation=plus
|GMAF=0.2668
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|effect1=
|effect2=
|effect3=
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 50.9 | 43.6 | 5.5
| HCB | 49.6 | 43.7 | 6.7
| JPT | 48.7 | 40.7 | 10.6
| YRI | 50.0 | 43.2 | 6.8
| ASW | 64.9 | 33.3 | 1.8
| CHB | 49.6 | 43.7 | 6.7
| CHD | 50.5 | 38.5 | 11.0
| GIH | 53.5 | 35.6 | 10.9
| LWK | 59.6 | 33.0 | 7.3
| MEX | 42.1 | 47.4 | 10.5
| MKK | 51.3 | 42.3 | 6.4
| TSI | 50.0 | 34.3 | 15.7
| HapMapRevision=28
}}{{PMID|19304784|OA=1
}} [[rs4954956]] was associated with increased [[ovarian cancer]] risk, particularly for serous ovarian cancer. The per minor allele odds ratio was 1.07 (CI: 1.01-1.13, P-trend=0.02) for all types of ovarian cancer and 1.14 (CI: 1.07-1.22, P-trend=0.00017) for serous ovarian cancer in this study of 2927 invasive ovarian cancer cases and 4143 controls from six ovarian cancer case-control studies.

{{omim
|id=167000
|rsnum=4954956
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}